Abstract
Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Anti-Cancer Agents in Medicinal Chemistry
Title: The Bright Future of Radionuclides for Cancer Therapy
Volume: 7 Issue: 3
Author(s): Johannes Franciscus Wilhelmus Nijsen, Gerard Cornelis Krijger and Afred Dirk van het Schip
Affiliation:
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Abstract: Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Export Options
About this article
Cite this article as:
Franciscus Wilhelmus Nijsen Johannes, Cornelis Krijger Gerard and Dirk van het Schip Afred, The Bright Future of Radionuclides for Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618207
DOI https://dx.doi.org/10.2174/187152007780618207 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis, Characterization and Anti-Listeria monocytogenes Effect of Amino Acid Coated Magnetite Nanoparticles
Current Nanoscience Metallothionein as a Negative Regulator of Pulmonary Inflammation
Current Pharmaceutical Biotechnology Modulation of Cancer Metabolism by Phytochemicals - A Brief Overview
Anti-Cancer Agents in Medicinal Chemistry Inwardly Rectifying Potassium Channels in the Regulation of Vascular Tone
Current Drug Targets Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis In Vitro and In Vivo
Current Cancer Drug Targets Rapid Screening of Antioxidant Active Constituents from Puerariae Lobatae Radix Based on the Investigation of Quantitative Patteren-Activity Relationship
Current Analytical Chemistry Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science Recent Advances in Liposomal Drug Delivery System of Quercetin for Cancer Targeting: A Mechanistic Approach
Current Drug Delivery Methods for Hydroxamic Acid Synthesis
Current Organic Chemistry Counteraction of Skin Inflammation and Aging or Cancer by Polyphenols and Flavonoids from Polypodium leucotomos and Xanthohumol
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Significant Association of miR-605 rs2043556 with Susceptibility to Breast Cancer
MicroRNA The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Vascular microRNAs
Current Drug Targets Controlled Release Inhalable Polymeric Microspheres for Treatment of Pulmonary Arterial Hypertension
Current Pharmaceutical Design ECMO for Refractory Hypoxia; Current State of the Art and Future Directions
Current Respiratory Medicine Reviews Nanomaterials-based Polymerase Chain Reactions for DNA Detection
Current Organic Chemistry Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Synthesis of Novel 1,4-Substituted 1,2,3-Triazoles by Water-Soluble (Salicyladimine) <sub>2</sub>Cu Complex Catalyzed Azide-Alkyne Cycloaddition in Water
Letters in Organic Chemistry